Owing to this property, the PI3K/AKT inhibitor, metformin, is being administered to HNSCC patients suffering from tissue hypoxia in order to evaluate the effect of metformin upon hypoxic conditions in tumor (NCT03510390). Here, PIK3CA is linked to head and neck squamous cell carcinoma.